Last reviewed · How we verify
NCT05759143
Enhancing Information Management for Young Adults After Genetic Cancer Risk Testing
NA trial testing Nest Platform in Genetic Predisposition to Disease in 40 participants. Currently enrolling.
30 March 2026
Quick facts
| Lead sponsor | Dana-Farber Cancer Institute |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | single group |
| Masking | none |
| Primary purpose | health services research |
| Enrollment | 40 |
| Start date | 1 May 2023 |
| Primary completion | 30 March 2026 |
| Estimated completion | 30 July 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Nest Platform
Conditions studied
- Genetic Predisposition to Disease — all drugs for Genetic Predisposition to Disease →
- Genetic Predisposition — all drugs for Genetic Predisposition →
Sponsor
Dana-Farber Cancer Institute
Who can join
Adults 18 to 39, any sex, with Genetic Predisposition to Disease or Genetic Predisposition. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This research is being done to develop the electronic platform Nest for young adults (ages 18-39) who have had prior cancer genetic testing. The platform will give patients and their clinicians access to continuously updated information about both pathogenic variants and variants of uncertain significance (VUS). The name of the intervention used in this research study is: Nest portal (electronic platform for patients and clinicians)
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05759143
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Genetic Predisposition to Disease
Currently open trials in the same condition.
- NCT06962059 — Healthy Volunteers Study · recruiting
- NCT07018128 — Expression of Genes Relating Hypertension and Efficacy of 4-7-8 Breathing Control on Reducing Blood Pressure · NA · recruiting
- NCT06399666 — Impact of Inflammatory Indexes and Gene Scores in Prediction of Atrial Fibrillation · recruiting
- NCT05772559 — Acute Myeloid Leukemia At Initial Diagnosis and/or Relapse in Children, Teenagers and Young Adults: Molecular Profiling, · recruiting
- NCT05524909 — Full-scale Intervention Study: Genetic Risk Communication and Wearables · NA · active not recruiting
Other Dana-Farber Cancer Institute trials
Trials by the same sponsor.
- NCT07519200 — Sexual Health and Rehabilitation for Women With Metastatic Breast Cancer (SHARE-MC): An Educational Intervention · NA · not yet recruiting
- NCT07499999 — Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk fo · Phase 2 · not yet recruiting
- NCT05825469 — Development and Testing of Nutritional Algorithms (NACHO) · NA · not yet recruiting
- NCT07516353 — my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults · NA · not yet recruiting
- NCT07513324 — Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0) · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05759143 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Dana-Farber Cancer Institute
- Last refreshed: 23 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05759143.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing